.tb-field[data-toolset-blocks-field="0c666225ea8a0a6a6fc3d524b619eaa3"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="4ece399e3f2d78d5fe8b8062b4842c70"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="c35d9a7279448f10d949ebc7e457ae45"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-field[data-toolset-blocks-field="627e912eb953c8ed786ea0c7e10207ea"] { font-size: 14px;text-align: left;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   h1.tb-heading[data-toolset-blocks-heading="4273ccf7ca31e5697065fdb41a036bd2"]  { font-size: 26px; }  .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

News and Press Releases

Advarra Integrates Study Startup and IRB Technologies, Enabling Unprecedented Visibility into Clinical Trial Site Activation

New release of Advarra’s Study Collaboration solution provides sponsors and CROs a single view into the progress of site activation milestones and IRB review status across sites 17 April 2025...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025

Advarra

6100 Merriweather Dr., Suite 600 Columbia, MD 21044

WCG ClinSphere Total Feasibility Releases Self-Serve Capabilities that Optimize Clinical Trial Site Selection

27 March 2025 -- North Carolina, US -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of WCG ClinSphere™ Total Feasibility's...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025

WCG Clinical

info@wcgclinical.com

212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Advarra Unveils Oncology Research Pulse

Content-driven program brings together clinical trial stakeholders to foster knowledge sharing and collaboration in cancer research 12 March 2025 -- Maryland, US -- Advarra, the market leader in regulatory review...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 12, 2025

Advarra

6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Advarra Introduces Comprehensive Solution to Accelerate Study Startup and Improve Collaboration on Trials

Proven technology powers end-to-end solution designed to streamline site activation workflows, improve engagement, and optimize visibility among trial stakeholders 21 January 2025 -- Maryland, US -- Advarra, the market leader...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: January 21, 2025

Advarra

6100 Merriweather Dr., Suite 600 Columbia, MD 21044

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

Zero refusals to file and a SOUL mindset helped solidify the honor 8 November 2024 -- Michigan, US -- MMS, a leading data and regulatory focused clinical research organization (CRO),...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 8, 2024

MMS Holdings

6880 Commerce Blvd. Canton, MI 48187 USA

Signant Health and SPRIM PRO Align to Advance eClinical Solutions for Specialized Clinical Research

30 October 2024 -- Pennsylvania, US -- Signant Health, the leader in evidence generation for modern clinical trials, today announced a strategic alignment with SPRIM PRO, a boutique contract research...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 30, 2024

Signant Health

media@signanthealth.com

4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462

Coronado Research Limited announce appointment of Professor Jennifer Visser-Rogers as Chief Scientific Officer

24 October 2024 -- London, UK -- Coronado Research announced today that Professor Jennifer Visser-Rogers has been appointed as Chief Scientific Officer. Jennifer brings with her a broad portfolio of...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: October 24, 2024

Coronado Research

datadriven@coronado-research.com

The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites

Advarra’s Gene Therapy Ready (GTR) global site network expands to better support and accelerate the rapidly growing number of CGT investigational new drugs through approval 3 October 2024 -- Maryland,...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 3, 2024

Advarra

6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Tracey Marantal Joins Worldwide Clinical Trials as President, Oncology Business Unit

Proven clinical operations leader joins global CRO to lead high-performing therapeutic team and drive strategy for growing oncology portfolio 24 September 2024 -- North Carolina, US -- Tracey Marantal has...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 24, 2024

Worldwide Clinical Trials

media@worldwide.com

600 Park Offices Drive Suite 200 Research Triangle Park, NC 27709 USA

Thermo Fisher Scientific’s Clinical Research Business Recognized by ISG for Digital Services Leadership

The PPD clinical research business has been named a leader in digital solutions and services by ISG for four consecutive years 14 August 2024 -- North Carolina, US -- The...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 15, 2024

PPD

929 North Front Street Wilmington, NC 28401-3331

Advarra Brings Together Clinical Trial Patient Recruitment Activities to Centralize Visibility and Accelerate Enrolment

New capability provides sponsors and CROs holistic view of sites’ patient recruitment progress 24 July 2024 -- COLUMBIA, MD – – Advarra, the market leader in regulatory review solutions and...

Category: Clinical Trials, Drug Discovery, Other
Posted: July 24, 2024

Advarra

6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Signant Health Appoints 20-Year Life Sciences Veteran Paul Richmond to executive leadership team as chief commercial officer

15 July 2024 – Pennsylvania, US – Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Paul Richmond as chief commercial officer. A...

Category: Clinical Trials, Other, Pharmaceutical
Posted: July 16, 2024

Signant Health

media@signanthealth.com

4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462

Mission Therapeutics awarded $5.2m from The Michael J Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease Marks latest step in Mission’s relationship with The Michael J Fox Foundation (MJFF), after...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024

Mission Therapeutics

info@missiontherapeutics.com

Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom

Thermo Fisher Scientific Expands Clinical Research Laboratory in Kentucky

The PPD clinical research business will nearly double its laboratory footprint in northern Kentucky, add more than 250 jobs 27 June 2024 -- North Carolina, US -- The PPD clinical...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 27, 2024

Thermo Fisher Scientific

168 Third Avenue Waltham, MA 02451

WCG and MRCT Center Form Task Force to Tackle Ethical Challenges in AI-Based Clinical Research

26 June 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, and the Multi-Regional Clinical Trials Center of Brigham...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 26, 2024